Literature DB >> 3392423

Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia.

M Thaler1, J Bacher, T O'Leary, P A Pizzo.   

Abstract

We developed an experimental model of candidiasis in rabbits with prolonged neutropenia. Rabbits were made neutropenic with cytosine arabinoside (Ara-C) administered through an indwelling silastic catheter that had been surgically implanted in the external jugular vein. Neutropenia was sustained with intravenous Ara-C, and bacterial complications were prevented with parenteral ceftazidime plus ampicillin. Candidiasis was established by intravenously administering Candida albicans or Candida tropicalis (1-2 x 10(5) colony-forming units) and resulted in hepatic and splenic lesions that mimicked those associated with hepatosplenic candidiasis in humans. The kidney proved to be the site most refractory to eradication of Candida spp. and offered a target organ for assessing antifungal therapy. We evaluated amphotericin B, 5-flucytosine, ketoconazole, and rifampin, alone and in combination. Although each agent reduced the colony counts of Candida in the liver, spleen, and lung, the combination of amphotericin B and 5-flucytosine was the only regimen effective in eradicating renal candidiasis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3392423     DOI: 10.1093/infdis/158.1.80

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Combination antifungal therapy for the treatment of invasive yeast and mold infections.

Authors:  John W Baddley; Peter G Pappas
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

Review 3.  Combination therapy for systemic mycosis.

Authors:  A Polak
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553

Review 4.  Chronic systemic candidiasis.

Authors:  G P Bodey; E J Anaissie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

5.  Hepatosplenic candidasis, a fatal disease?

Authors:  A Loeliger; M van Leeuwen; M Rozenberg-Arska; A W Dekker
Journal:  Infection       Date:  1992-11       Impact factor: 3.553

6.  SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits.

Authors:  T J Walsh; J W Lee; J Lecciones; P Kelly; J Peter; V Thomas; J Bacher; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

7.  Diagnostic laparoscopy in patients with acute leukemia and suspected hepatic candidiasis.

Authors:  V J Anttila; M Färkkilä; S E Jansson; M Taavitsainen; S S Kaukoranta-Tolvanen; S Nordling; P Koukila-Kähkölä; T Ruutu; P Ruutu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-09       Impact factor: 3.267

8.  In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.

Authors:  D Andes; M van Ogtrop
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 9.  Treatment of systemic fungal infections: recent progress and current problems.

Authors:  T J Walsh; A Pizzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

Review 10.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.